LumaCyte Expands into Europe Tackling Expansive Vaccine and Cell and Gene Therapy Markets
February 20 2020 - 7:07AM
Business Wire
LumaCyte, an advanced bioanalytical instrumentation company
specializing in vaccine and cell and gene therapy bioprocess,
production, and R&D analytical capabilities, announces its
expansion into Europe with the establishment of LumaCyte, B.V. in
The Netherlands. LumaCyte has experienced a rapid increase in
global demand for Radiance®, it’s label-free single cell analysis
instrument, with a large portion of that demand coming from Europe.
In the fall of 2019, LumaCyte reported that it was strengthening
its infrastructure to support a growing customer base, with strong
efforts being placed on servicing the expansive European market.
The company has expanded its US headquarters, significantly
increasing manufacturing and laboratory footprints, as well as
completed the rigorous EU specific regulatory CE mark
certification, indicating Radiance® conformity with EEA health and
safety standards, which is a prerequisite for its instrument sale
and use.
The vaccine and cell and gene therapy biomanufacturing sectors
are growing at an accelerated rate with the US and Europe driving a
significant segment of this growth. “European biopharma and CDMO
scientists often ask if we have representation in the region as
they search for innovative tools to alleviate their production and
QC bottlenecks; we can now finally say yes to this important
question," says Dr. Sean Hart, LumaCyte’s Chief Executive Officer.
In support of these efforts, LumaCyte has hired analytical
instrumentation veteran, Christof Hasse, PhD to manage sales and
service as part of its European expansion. “At LumaCyte, we’re
obsessed with delivering exceptional customer service, so having
Laser Force Cytology™ (LFC) experts who understand our customers’
unique needs, and are located in the same region, is critical to
delivering the highest level of service, says Renée Hart, LumaCyte
President and Chief Business Officer. We are excited to have
Christof on board as he brings LumaCyte’s transformative Laser
Force Cytology™ to the hands of European researchers and production
scientists.”
About LumaCyte
LumaCyte is an advanced research and bioanalytics
instrumentation company headquartered in Charlottesville, VA.
LumaCyte produces label-free, single cell analysis and sorting
instrumentation where the use of antibody or genetic labeling is
not required for cellular analysis. This revolutionary technology
utilizes Laser Force Cytology™ (LFC™) to measure optical and
fluidic forces within a microfluidic channel to identify and
measure the intrinsic cellular properties of each cell. The
multivariate nature of the data has enabled a host of Big Data
strategies and cloud computing capabilities that drive advanced
analytics, allowing a deeper understanding of cell based biological
systems. Applications of LumaCyte's label-free platform technology
include viral infectivity for vaccine development and
manufacturing, cell and gene therapy, cancer biology R&D, CAR T
cell immunotherapy, adventitious agent testing (AAT), iPSCs,
infectious disease, and pre-clinical drug discovery, in addition to
multiple applications across the biomanufacturing sector for
quality control and process optimization.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200220005263/en/
Renee Hart renee.hart@lumacyte.com 888-472-9295